Healthcare
Live Price
Offline$12.87
+1.77% today
1Y Change
+24.18%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharming Group N.V. (PHAR) is a Healthcare stock with a market cap of $1.19B and listed on NASDAQ. The stock last traded around $12.87 and up 24.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +26.9%, EPS growth of +123.5%, a dividend yield of 0.0%. What stands out right now is revenue +26.9%, EPS +123.5%, free cash flow +2003.3% with operating margin 5.7% and ROIC 1.1%. Valuation already assumes a fairly strong business story at P/E 385.8 and price/sales 3.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PHAR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHAR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHAR Max Drawdown
-43.34%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHAR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$198.9M
-3.3% YoY
FY Net Income
$16.0M
+17.0% YoY
Free Cash Flow
$21.1M
+3.1% YoY
Revenue Growth
+26.9%
EPS Growth
+123.5%
Gross Margin
87.9%
Net Margin
0.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 377M | 297M | 245M | 206M | 199M |
| Gross Profit | 332M | 262M | 220M | 188M | 178M |
| Operating Income | 19M | -9M | -5M | 18M | 14M |
| EBITDA | 31M | 16M | 10M | 34M | 49M |
| Net Income | 3M | -12M | -11M | 14M | 16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 146M | 55M | 62M | 207M | 192M |
| Total Assets | 500M | 400M | 463M | 426M | 397M |
| Total Liabilities | 223M | 179M | 244M | 221M | 204M |
| Shareholder Equity | 277M | 221M | 219M | 205M | 193M |
| Total Debt | 116M | 112M | 172M | 167M | 162M |
| Net Debt | -30M | 57M | 110M | -41M | -30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
38M
+68.5% YoY
Capital Expenditures
17M
-745.5% YoY
Free Cash Flow
21M
+3.1% YoY
Key ratios
Gross Margin
87.9%
Operating Margin
5.7%
Net Margin
0.8%
ROE
1.2%
Debt / Equity
0.42x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.